SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, has closed an oversubscribed EUR50 million series A financing co-led by UCB Ventures and existing shareholder Ysios Capital.
New investors New Enterprise Associates (NEA), Gilde Healthcare, Novartis Venture Fund, and existing shareholder Asabys Partners also particpated.
The Company was seeded in 2020 by Ysios Capital and Asabys Partners.
The proceeds from the financing, the largest Series A round for a Spanish biotech company, will enable SpliceBio to build a pipeline of Protein Splicing gene therapy programmes, while advancing the lead program in Stargardt disease to the clinic.
